NCT04718727

Olanzapine for the Prevention of Postoperative Nausea and Vomiting

Olanzapine for the Prevention of Postoperative Nausea and Vomiting After Laparoscopic Surgery in High-risk Patients: A Randomized Controlled Trial

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 132 (actual)
• Sponsor: Amani Hassan Abdel-Wahab · Academic / Other
• Sex: Female
• Age: 18 Years – 50 Years
• Healthy volunteers: Not accepted

Summary

Nausea and vomiting (PONV) remain a common problem in surgical units. Even after two or three prophylactic antiemetic interventions, patients with all four of the Apfel risk factors for PONV have an estimated 30 to 40% chance of suffering PONV. Olanzapine as an antiemetic represents a new use of an antipsychotic drug.

Detailed description

Aim of the Research, to compare the effects of oral 10 and 5 mg Olanzapine for the Prevention of Postoperative Nausea and Vomiting

Conditions

• Postoperative Nausea

Interventions

Type	Name	Description
DRUG	Placebo	oral Placebo tablets one-hour preoperatively
DRUG	5 mg Olanzapine Tablets	oral 5 mg Olanzapine tablets one-hour preoperatively
DRUG	10 mg Olanzapine Tablets	oral 10 mg Olanzapine tablets one-hour preoperatively

Timeline

• Start date: 2021-03-15
• Primary completion: 2023-02-01
• Completion: 2023-02-01
• First posted: 2021-01-22
• Last updated: 2023-03-09

Locations

2 sites across 1 country: Egypt